Cefuroxime

Cephalosporin Antibacterial — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Cefuroxime is an ofp drug in the Cephalosporin Antibacterial class catalogued in DrugCentral. It was first approved by the FDA in 1983. DrugCentral lists 5 molecular targets, including CA2, MMP9 and MMP2. Recorded indications include Acute bacterial sinusitis, Acute exacerbation of chronic bronchitis, Acute gonococcal cervicitis and Acute gonococcal endometritis.

• Approval status: ofp (first approved 1983 by the FDA).
• Drug class: Cephalosporin Antibacterial.
• Molecular targets: CA2, MMP9, MMP2 and pbpA (5 listed in DrugCentral).
• Indications: Acute bacterial sinusitis, Acute exacerbation of chronic bronchitis, Acute gonococcal cervicitis, Acute gonococcal endometritis and Acute gonococcal urethritis and others.
• ATC code: J01DC02 (Second-generation cephalosporins).
• Molecular formula: C16H16N4O8S; molecular weight 424.38 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (54)

• Acute bacterial sinusitis
• Acute exacerbation of chronic bronchitis
• Acute gonococcal cervicitis
• Acute gonococcal endometritis
• Acute gonococcal urethritis
• Acute maxillary sinusitis
• Acute otitis media
• Bacterial infection due to Klebsiella pneumoniae
• Bacterial meningitis
• Bacterial pneumonia
• Bacterial septicemia
• Bacterial urinary infection
• Disseminated Gonococcal Infection
• Escherichia coli urinary tract infection
• Gonorrhea
• Gonorrhea of pharynx
• Gonorrhea of rectum
• H. Influenzae Meningitis
• Haemophilus Influenzae Acute Otitis Media
• Haemophilus Influenzae Bronchitis
• Haemophilus Influenzae Chronic Bronchitis
• Haemophilus influenzae pneumonia
• Haemophilus Parainfluenzae Bronchitis
• Haemophilus Parainfluenzae Chronic Bronchitis
• Haemophilus Septicemia
• Impetigo
• Infection due to Enterobacteriaceae
• Infection due to Escherichia coli
• Infection due to Staphylococcus aureus
• Infection of bone
• + 24 more

Off-label uses (4)

• Neonatal meningitis
• Neonatal pneumonia
• Pyrexia of unknown origin
• Sepsis of the newborn

Contraindications (5)

• Blood coagulation disorder
• Disease of liver
• Factor II deficiency
• Kidney disease
• Pseudomembranous enterocolitis

Mechanism & targets

• Established pharmacologic class: Cephalosporin Antibacterial

Molecular targets (5)

Target	Gene	Action	Activity
Carbonic anhydrase 2	CA2	unknown	IC50 5.92
Matrix metalloproteinase-9	MMP9	unknown	IC50 4.96
72 kDa type IV collagenase	MMP2	unknown	IC50 4.37
Penicillin-binding protein 1A	pbpA	unknown	—
Bacterial penicillin-binding protein	mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1983-10-19	FDA	—	COVIS INJECTABLES

ATC classification

ATC code	Therapeutic hierarchy
J01DC02	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Second-generation cephalosporins
J01DC52	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Second-generation cephalosporins
J01RA03	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › COMBINATIONS OF ANTIBACTERIALS › Combinations of antibacterials
S01AA27	SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFECTIVES › Antibiotics

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Pulmonary vasculitis	447.9
Anaphylactic shock	445.3
Anaphylactic reaction	428.4
Neuritis	371.0
Eosinophilic granulomatosis with polyangiitis	322.0
Total lung capacity abnormal	305.3
Respiratory symptom	301.4
Neurological symptom	264.8
Pulmonary alveolar haemorrhage	264.8
Spirometry abnormal	257.7
Macular oedema	244.0
Conjunctivitis allergic	228.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Cefuroxime is on its molecule page.

• Molecular formula: C₁₆H₁₆N₄O₈S
• Molecular weight: 424.38 g/mol
• CAS number: 55268-75-2
• InChIKey: JFPVXVDWJQMJEE-IZRZKJBUSA-N
• PubChem CID: 5479529

CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)C1=CC=CO1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Cefuroxime used for?

DrugCentral lists the following indications for Cefuroxime: Acute bacterial sinusitis, Acute exacerbation of chronic bronchitis, Acute gonococcal cervicitis, Acute gonococcal endometritis, Acute gonococcal urethritis, Acute maxillary sinusitis, Acute otitis media and Bacterial infection due to Klebsiella pneumoniae and others.

How does Cefuroxime work?

Its molecular targets in DrugCentral include CA2, MMP9, MMP2 and pbpA.

When was Cefuroxime first approved?

Cefuroxime was first approved by the FDA in 1983.

What drug class does Cefuroxime belong to?

Cefuroxime is in the Cephalosporin Antibacterial class.

What is the chemical formula of Cefuroxime?

Cefuroxime has the molecular formula C16H16N4O8S and a molecular weight of 424.38 g/mol.

Sources

• DrugCentral drug card 565 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1436 — compound record and bioactivity
• PubChem CID 5479529 — chemical identifiers
• DrugBank DB01112 — drug record
• FDA UNII O1R9FJ93ED — substance identity
• DailyMed: FDA labels for Cefuroxime — current prescribing information (label search)
• UniProt P00918 (CA2) — target protein
• UniProt P14780 (MMP9) — target protein
• UniProt P08253 (MMP2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.